XNYS
JNJ
Market cap623bUSD
Oct 20, Last price
258.52USD
1D
2.19%
1Q
1.46%
Jan 2017
125.12%
Name
Johnson & Johnson
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Johnson & Johnson functions as a global healthcare enterprise, involved in the research, development, manufacturing, and commercialization of a wide spectrum of health-related products. Its activities are organized across three principal divisions: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment provides an extensive range of goods, encompassing baby care items under brands like JOHNSON'S and AVEENO Baby, oral hygiene products such as LISTERINE, and skin/beauty solutions from AVEENO, NEUTROGENA, and OGX. It also offers over-the-counter medications for various ailments, including pain relief (TYLENOL, MOTRIN IB), cold, flu, and allergy symptoms (SUDAFED, BENADRYL, ZYRTEC), smoking cessation aids (NICORETTE), and acid reflux treatments (PEPCID). Additionally, this division includes women's health products like STAYFREE and o.b., wound care essentials such as BAND-AID adhesive bandages, and NEOSPORIN for first aid. The Pharmaceutical segment is dedicated to developing therapies within significant therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic disorders. The Medical Devices segment delivers sophisticated solutions for cardiovascular conditions, including electrophysiology and neurovascular care for strokes. It also provides orthopaedic products supporting hips, knees, trauma, spine, and sports-related needs, alongside advanced and general surgical solutions focusing on breast aesthetics and ear, nose, and throat procedures. Furthermore, this segment offers ophthalmic products, notably ACUVUE brand disposable contact lenses and technologies for cataract and laser refractive surgery. The company distributes its products through diverse channels, reaching the general public via retail outlets and distributors, and directly supplying wholesalers, hospitals, and healthcare professionals for prescription-based use. Johnson & Johnson was established in 1886 and maintains its headquarters in New Brunswick, New Jersey.
Related entities
Subsidiaries (205)
ACCLARENT, INC.
ACTELION PHARMACEUTICALS US, INC.
ACTELION TREASURY UNLIMITED COMPANY
ALZA CORPORATION
AMO (HANGZHOU) CO., LTD.
AMO ASIA LIMITED
AMO HOLDINGS, INC.
AMO SALES AND SERVICE, INC.
AURIS HEALTH, INC.
BEIJING DABAO COSMETICS CO., LTD.
BIOMEDICAL ENTERPRISES, INC.
Biosense Webster (Israel) Ltd.
BIOSENSE WEBSTER, INC.
Cilag Holding AG
CORDIS FINANCING CORPORATION
DEPUY SYNTHES PRODUCTS, INC.
DEPUY SYNTHES SALES, INC.
DEPUY SYNTHES, INC.
ETHICON ENDO-SURGERY (EUROPE) GMBH
ETHICON ENDO-SURGERY, INC.
Key people
Chairman of the Board, Chief Executive Officer · since 2023
Chief Financial Officer, Executive Vice President · since 2018
Executive Vice President - Global Corporate Affairs · since 2022
Elizabeth Forminard
Executive Vice President, Chief Legal Officer · since 2022
Kristen Mulholland
Chief Human Resources Officer, Executive Vice President · since 2024
John Reed
Executive Vice President - Innovative Medicine, Research and Development · since 2023
Tim Schmid
Executive Vice President, Worldwide Chairman of MedTech · since 2023
James Swanson
Executive Vice President, Chief Information Officer · since 2022
Executive Vice President, Worldwide Chairman, Innovative Medicine · since 2018
Executive Vice President, Chief Technology Officer and Risk Officer · since 2023
Lead Independent Director · since 2024
Darius Adamczyk
Independent Director · since 2022
Independent Director · since 2015
Jennifer Doudna
Independent Director · since 2018
Independent Director · since 2023
Independent Director · since 2019
Independent Director · since 2013
Independent Director · since 2025
Independent Director · since 2024
Independent Director · since 2019
Headquarters & legal address
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
US
New Brunswick, NJ 08933
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑00 | 2021‑00 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||